Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis

Nazir, Jameel; Kelleher, Con; Aballéa, Samuel; Maman, Khaled; Hakimi, Zalmaï; Mankowski, Colette; Odeyemi, Isaac

doi:10.1002/nau.23413

Cited by 15 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We conducted a Bayesian NMA to estimate the relative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinics in patients with OAB [13]. The NMA included 53 RCTs, identified from a systematic literature search performed in 2015 [13]; the NMA data used in our model are presented in Table S1.…”

Section: Methodsmentioning

confidence: 99%

“…For other antimuscarinics, odds ratios from the NMA [13] (Table S1) were used to adjust the probability of each AE (Table 1). …”

Section: Methodsmentioning

confidence: 99%

“…Although many cost-effectiveness analyses of antimuscarinic agents in OAB have been performed, most compare only two agents over a short time-frame based on available data from RCTs and therefore provide only limited economic data to guide clinical decision-makers. By applying data from a recent network meta-analysis (NMA) [13] to a Markov model for OAB [14,15], we constructed a single analysis to evaluate the long-term (5-year) cost-effectiveness of solifenacin 5 mg/day compared with several other oral antimuscarinics routinely prescribed for adults with OAB from a UK National Health Service (NHS) perspective.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Hakimi

Kelleher

Aballéa

et al. 2018

Journal of Market Access & Health Policy

Self Cite

View full text Add to dashboard Cite

Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted life year (QALY) over a 5-year period. Results: Solifenacin 5 mg/day was the dominant treatment strategy (i.e., less costly and more effective) versus tolterodine extended-release (ER) 4 mg/day, fesoterodine 4 and 8 mg/day, oxybutynin ER 10 mg/day and solifenacin 10 mg/day, and was cost-effective (i.e., ICERs below the £30,000 per QALY threshold generally applied in the NHS) versus oxybutynin immediate release (IR) 10 mg/day, tolterodine IR 4 mg/day and trospium chloride 60 mg/day. The probability of solifenacin 5 mg/day being dominant/cost-effective at a willingness-to-pay threshold of £30,000 per QALY was 57–98%. Conclusions: Solifenacin 5 mg/day appears to be a cost-effective strategy for the treatment of OAB over a 5-year timeframe compared with other oral antimuscarinic agents in the UK. These findings are important for decision-makers considering the economic implications of selecting treatments for OAB.

show abstract

Section: Methodsmentioning

confidence: 99%

“…For other antimuscarinics, odds ratios from the NMA [13] (Table S1) were used to adjust the probability of each AE (Table 1). …”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Hakimi

Kelleher

Aballéa

et al. 2018

Journal of Market Access & Health Policy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dengan kata lain, penggunaan imidafenacin tidak menghasilkan efek positif terhadap pasien yang lebih superior dibandingkan dengan pembanding termasuk tolterodine, fesoterodine, propiverine, dan solifenacin. Ditinjau dari sisi keamanan penggunaan, imidafenacin lebih jarang menyebabkan ROTD berupa mulut kering (relative risk [RR] 0,87; 95% confidence interval [CI] 0,75-1,00) dan konstipasi (RR 0,68; 95% CI 0,50-0,93) bila dibandingkan dengan golongan anti-muskarinik lainnya (Huang, et al, 2015;Nazir, et al, 2018;Wu, et al, 2020). Namun demikian, kejadian jenis ROTD yang lain relatif tidak berbeda secara signifikan antara kelompok yang mendapat imidafenacin dan antimiskarinik lain yang ada di Indonesia.…”

Section: Efektivitas Dan Keamanan Imidafenacinunclassified

Literature Review: Efektivitas, Keamanan, dan Biaya Terapi Imidafenacin untuk Pasien Overactive Bladder

Halim

2020

View full text Add to dashboard Cite

Imidafenacin is a new antimuscarinic agent in Indonesia that was recently approved in 2019 to treat overactive bladder (OAB) symptoms, including urinary incontinence, urinary frequency, and urinary urgency. As a new OAB medication in the Indonesian commercial market, a comprehensive review on the efficacy, safety, and cost of imidafenacin are essentially needed to optimize the responsible use of this drug, particularly in the era of universal coverage implementation in Indonesia. This review aimed to describe the profile of imidafenacin and to compare the efficacy, safety, and cost of imidafenacin with the other antimuscarinic drugs in Indonesia, and the guideline recommendations towards when to use imidafenacin for OAB treatment. Only results from systematic reviews and meta-analyses were used in the efficacy and safety comparison. Our review found that the efficacy of imidafenacin was relatively comparable to the other antimuscarinic drugs in Indonesia, including solifenacin, tolterodine, dan propiverine. Also, a better safety profile was found in the imidafenacin group, in particular, imidafenacin caused less dry mouth and constipation. This could be attributable to the higher affinity of imidafenacin to the M3 receptor resulting in less antimuscarinic effect at the other receptors. From the cost perspective, the cost of medication by using imidafenacin was relatively lower compared to the other antimuscarinic drugs in Indonesia. It, therefore, could be suggested to use imidafenacin as a potential agent for OAB.

show abstract

“…It has been reported that different anticholinergics exhibit different effects and, depending on the type, dosage, and formulation type, adverse reactions may occur (Level 1). However, no reports have evaluated the superiority or inferiority of each type 37,38.…”

mentioning

confidence: 99%

Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition)

Takahashi¹,

Takei²,

Asakura³

et al. 2021

Int J of Urology

View full text Add to dashboard Cite

The present article is an abridged English translation of the Japanese Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition), published in September 2019. These guidelines consist of a total of 212 pages and are unique worldwide in that they cover female lower urinary tract symptoms other than urinary incontinence. They contain two algorithms for "primary treatment" and "specialized treatment," respectively. These guidelines, consisting of six chapters, address a total of 26 clinical questions including: (i) treatment algorithms; (ii) what are female lower urinary tract symptoms?; (iii) epidemiology and quality of life; (iv) pathology and illness; (v) diagnosis; and (vi) treatment. When the patient's symptoms mainly involve voiding and post-micturition symptoms, specialized treatment should be considered. In the event of voiding symptoms concurrent with storage symptoms, residual urine should be measured; if the residual urine volume is <100 mL, then diagnosis and treatment for storage symptoms is prioritized, and if the volume is ≥100 mL, then specialized treatment should be considered. When storage symptoms are the primary condition, then the patient is subject to the primary treatment algorithm. Specialized treatment for refractory overactive bladder includes botulinum toxin injection and sacral nerve stimulation. For stress urinary incontinence, surgical treatment is indicated, such as urethral slings. The two causes of voiding symptoms and post-micturition symptoms are lower urinary tract obstruction and detrusor underactivity (underactive bladder). Mechanical lower urinary tract obstruction, such as pelvic organ prolapse, is expected to improve with surgery.

show abstract

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta‐analysis

Cited by 15 publications

References 31 publications

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Literature Review: Efektivitas, Keamanan, dan Biaya Terapi Imidafenacin untuk Pasien Overactive Bladder

Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition)

Contact Info

Product

Resources

About